All In Biotech

Drug Trial Radar · NCT07350018

Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome

Comparison of the Efficacy of Calfactant and Poractant Alfa Surfactants Administered by a Less Invasive Surfactant Administration Technique in Preterm Infants With Respiratory Distress Syndrome

Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

234

Planned (sponsor's estimate)

Start

Jan 20, 2026

Primary completion

Feb 20, 2027

Study completion Feb 20, 2027

Sponsor

Lead sponsor
Uludag UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 hours, up to 6 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Respiratory distress syndrome (RDS) is a common cause of respiratory failure in preterm infants and is frequently treated with surfactant therapy. With the increasing use of noninvasive ventilation, less invasive methods of surfactant administration have been developed. In the technique known as Less Invasive Surfactant Administration (LISA), surfactant is delivered into the trachea through a thin catheter, without the need for endotracheal intubation. This approach may reduce lung injury and improve respiratory outcomes in spontaneously breathing preterm infants. This multicenter, prospective, randomized study aims to compare the clinical effectiveness of poractant alfa and calfactant when administered using the LISA technique in preterm infants born at less than 30 weeks' gestation with RDS who are not intubated. The study will evaluate short-term outcomes, including the need for intubation, repeat surfactant administration, and respiratory support during the first 72 hours of life, as well as longer-term outcomes such as bronchopulmonary dysplasia and other neonatal morbidities.

Conditions

  • Respiratory Distress Syndrome in Premature Infants
  • Respiratory Distress Syndrome (RDS)
  • Surfactant

Interventions

  • Poractant alfaDrug

    Poractant alfa will be administered using the Less Invasive Surfactant Administration (LISA) technique. A thin catheter will be inserted into the trachea under direct laryngoscopic visualization, without the need for endotracheal intubation, while the infant continues to breathe spontaneously on noninvasive respiratory support. Dosing and administration will follow standard clinical guidelines. (200 mg/kg initial dose, 100 mg/kg repeat dose)

  • CalfactantDrug

    Calfactant will be administered using the Less Invasive Surfactant Administration (LISA) technique. A thin catheter will be inserted into the trachea under direct laryngoscopic visualization, without the need for endotracheal intubation, while the infant continues to breathe spontaneously on noninvasive respiratory support. Dosing and administration will follow standard clinical guidelines. (100 mg/kg initial and repeat dose)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Need for endotracheal intubation within the first 72 hours of lifeTime frame: Up to 72 hours after birth.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Bursa City Hospital

    Bursa, Turkey (Türkiye) · Recruiting

  • Division of Neonatology, Department of Pediatrics, Bursa Uludağ University Faculty of Medicine

    Bursa, Turkey (Türkiye) · Recruiting

  • Division of Neonatology, Department of Pediatrics, University of Health Sciences Bursa Yuksek İhtisas Training and Research Hospital

    Bursa, Turkey (Türkiye) · Recruiting

  • Dörtçelik Children's Diseases Hospital

    Bursa, Turkey (Türkiye) · Recruiting

  • Medicana Bursa Hospital

    Bursa, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.